manufacture and commercialise the drug candidate “SON-080” for the treatment of diabetic peripheral neuropathy in India. According to a press statement, “SON-080” is Sonnet’s proprietary ...

(4) Denervated bands of Schwann cells. Multifocal diabetic neuropathy. Cross section of a paraffin-embedded superficial peroneal nerve specimen from a patient with a subacute progressive ...

Peripheral neuropathy is a serious complication ... There is currently no effective treatment for diabetic neuropathy, and good glycemic control is the only way to minimize the risk of occurrence ...

Neuro-immune interactions in specific contexts, such as diabetic and chemotherapy-induced peripheral neuropathy. 5. The impact of peripheral neuropathy-mediated ... Clinical trials and case studies ...

︎ Diabetic peripheral neuropathy, which affects about 30% of diabetics ... Beyond lifestyle modifications and keeping good control of your blood sugars, there are treatment options available to reduce ...

Mumbai: Alkem Laboratories Ltd. has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc to develop, manufacture and commercialise the drug candidate “SON-080” for the ...

Peripheral neuropathy, a condition affecting millions of people worldwide, can cause chronic pain, numbness, and weakness, particularly in the hands and feet. While traditional treatments for ...

Brad Axis Brain and Back Institute +1 (817) 502-7411 ... Visit us on social media: Facebook X LinkedIn YouTube ...

Jiangsu Alicorn Pharmaceutical Co. Ltd. has described AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s ...

Peripheral neuropathy is a complex and often debilitating condition that affects millions of people worldwide. Research estimates around 10% of the general population experiences some form of ...